Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company) has appointed Shana Neal as the new chief people officer, effective April 4, 2022. Neal, who previously held various HR positions at BD from 2005 to 2018, will oversee global HR functions, including Talent Acquisition, Total Rewards, and Diversity initiatives. She replaces Betty Larson, who is transitioning to a new role in the healthcare sector. BD's CEO Tom Polen expressed confidence in Neal's leadership skills and industry knowledge as essential for advancing BD's 2025 strategy and enhancing stakeholder value.
BD (Becton, Dickinson and Company) announced that its diabetes care business, embecta, will spin off on April 1, 2022. To prepare investors, embecta will host a virtual Investor Event on March 7, 2022, starting at 8 a.m. Eastern Time. Presenters include CEO Dev Kurdikar and CFO Jake Elguicze, discussing the company's products, market opportunities, and financial strategies. A Q&A session will follow. More details and a link to the event are available on BD's investor webpage, with a replay accessible post-event.
Summary not available.
BD (Becton, Dickinson and Company) reported Q1 FY2022 results with revenues of $4,995 million, down 6% from the previous year. Base revenues rose 8.1%, driven by strong performance in BD Medical, which grew 6% to $2,397 million. However, the BD Life Sciences segment saw a significant decline of 25% due to lower COVID-19 testing revenues. The company raised its FY2022 revenue guidance to $19.55-$19.75 billion and adjusted EPS to $12.80-$13.00. BD continues to focus on innovation, M&A, and ESG initiatives, while also navigating currency headwinds.
On February 1, 2022, BD (Becton, Dickinson and Company) announced its board of directors approved the spinoff of its diabetes care business, set to become Embecta Corp. The spinoff will take effect on April 1, 2022, with BD shareholders receiving one share of Embecta stock for every five shares of BD owned by March 22, 2022. The move aims to sharpen BD's focus on its core growth strategies and enhance Embecta's capacity for capital attraction and innovation in diabetes management. The IRS has deemed the transaction tax-free for U.S. federal income tax purposes.
BD (Becton, Dickinson and Company) has acquired Cytognos, a Spanish firm specializing in flow cytometry solutions for blood cancer diagnostics. This move enhances BD’s portfolio by integrating advanced assays for monitoring minimal residual disease (MRD) and improving cancer care. Cytognos brings over 25 years of expertise, complementing BD’s existing products and expanding its reach in chronic disease management. The acquisition, expected to be immaterial to BD's fiscal 2022 results, strengthens existing collaborations with the EuroFlow Consortium.
Summary not available.
BD (Becton, Dickinson and Company) announced a peer-reviewed study in Obstetrics & Gynecology highlighting the effectiveness of molecular diagnostics in diagnosing vaginitis. The study found that clinician assessments missed 45.3% of positive cases and incorrectly identified 12.3% of negative cases. With vaginitis affecting 6 to 10 million women annually in the U.S., this study emphasizes the need for accurate diagnostic tools. The BD MAX™ Vaginal Panel Assay provides quicker and more accurate results, enhancing treatment decisions for patients.
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share. This dividend is scheduled for payment on March 31, 2022, to shareholders of record as of March 10, 2022. The indicated annual dividend rate stands at $3.48 per share, reflecting BD's commitment to returning value to its shareholders.
BD (Becton, Dickinson and Company) announced a significant advancement in flow cytometry through its new BD CellView™ Image Technology, highlighted in the journal Science. This technology allows for the sorting of individual cells at speeds of up to 15,000 cells per second, integrating fluorescence imaging for enhanced analysis. The system captures detailed images, enabling precise identification of biomarkers and their distributions, which could accelerate research in immunology and genomics. The technology promises to transform cell-based therapeutic discovery, filling long-standing gaps in biomedical research.